These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 7784060)

  • 1. Expression of antisense osteopontin RNA inhibits tumor promoter-induced neoplastic transformation of mouse JB6 epidermal cells.
    Su L; Mukherjee AB; Mukherjee BB
    Oncogene; 1995 Jun; 10(11):2163-9. PubMed ID: 7784060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteopontin induction is required for tumor promoter-induced transformation of preneoplastic mouse cells.
    Chang PL; Cao M; Hicks P
    Carcinogenesis; 2003 Nov; 24(11):1749-58. PubMed ID: 12919959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transforming JB6 cells exhibit enhanced integrin-mediated adhesion to osteopontin.
    Chang PL; Chambers AF
    J Cell Biochem; 2000 Apr; 78(1):8-23. PubMed ID: 10797562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1 alpha,25-Dihydroxyvitamin D3 enhances 12-O-tetradecanoylphorbol-13-acetate- induced tumorigenic transformation and osteopontin expression in mouse JB6 epidermal cells.
    Chang PL; Prince CW
    Cancer Res; 1993 May; 53(10 Suppl):2217-20. PubMed ID: 8485706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA.
    Behrend EI; Craig AM; Wilson SM; Denhardt DT; Chambers AF
    Cancer Res; 1994 Feb; 54(3):832-7. PubMed ID: 8306346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts.
    Gardner HA; Berse B; Senger DR
    Oncogene; 1994 Aug; 9(8):2321-6. PubMed ID: 8036014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dominant-negative c-Jun (TAM67) target genes: HMGA1 is required for tumor promoter-induced transformation.
    Dhar A; Hu J; Reeves R; Resar LM; Colburn NH
    Oncogene; 2004 May; 23(25):4466-76. PubMed ID: 15064752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisense downregulation of a mouse mammary tumor virus activated protooncogene in mouse mammary tumor cells reverses the malignant phenotype.
    Li YX; Papkoff J; Sarkar NH
    Virology; 1999 Mar; 255(1):138-49. PubMed ID: 10049829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transfer by pro gene transfection of tumor promoter-sensitive phenotype to promotion-insensitive JB6 cells.
    Colburn NH; Smith BM; Wendel EJ; Dowjat WK; Shimada T
    Cancer Res; 1988 Mar; 48(5):1195-200. PubMed ID: 3342399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor promoter-induced ornithine decarboxylase gene expression occurs independently of AP-1 activation.
    Jansen AP; Colburn NH; Verma AK
    Oncogene; 1999 Oct; 18(42):5806-13. PubMed ID: 10523861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells.
    Tuck AB; Arsenault DM; O'Malley FP; Hota C; Ling MC; Wilson SM; Chambers AF
    Oncogene; 1999 Jul; 18(29):4237-46. PubMed ID: 10435636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1 alpha,25-dihydroxyvitamin D3 stimulates synthesis and secretion of nonphosphorylated osteopontin (secreted phosphoprotein 1) in mouse JB6 epidermal cells.
    Chang PL; Prince CW
    Cancer Res; 1991 Apr; 51(8):2144-50. PubMed ID: 2009532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor promoter induces high mobility group HMG-Y protein expression in transformation-sensitive but not -resistant cells.
    Cmarik JL; Li Y; Ogram SA; Min H; Reeves R; Colburn NH
    Oncogene; 1998 Jul; 16(26):3387-96. PubMed ID: 9692546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of tumor promoter-induced transformation by retinoids that transrepress AP-1 without transactivating retinoic acid response element.
    Li JJ; Dong Z; Dawson MI; Colburn NH
    Cancer Res; 1996 Feb; 56(3):483-9. PubMed ID: 8564958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation.
    Senger DR; Perruzzi CA; Papadopoulos A
    Anticancer Res; 1989; 9(5):1291-9. PubMed ID: 2686530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered sialylation of osteopontin prevents its receptor-mediated binding on the surface of oncogenically transformed tsB77 cells.
    Shanmugam V; Chackalaparampil I; Kundu GC; Mukherjee AB; Mukherjee BB
    Biochemistry; 1997 May; 36(19):5729-38. PubMed ID: 9153413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-induced transmembrane 3 binds osteopontin in vitro: expressed in vivo IFITM3 reduced OPN expression.
    El-Tanani MK; Jin D; Campbell FC; Johnston PG
    Oncogene; 2010 Feb; 29(5):752-62. PubMed ID: 19901966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisense expression for amphiregulin suppresses tumorigenicity of a transformed human breast epithelial cell line.
    Ma L; Gauvillé C; Berthois Y; Millot G; Johnson GR; Calvo F
    Oncogene; 1999 Nov; 18(47):6513-20. PubMed ID: 10597254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cells in vivo and in vitro from osteopetrotic mice homozygous for c-src disruption show suppression of synthesis of osteopontin, a multifunctional extracellular matrix protein.
    Chackalaparampil I; Peri A; Nemir M; Mckee MD; Lin PH; Mukherjee BB; Mukherjee AB
    Oncogene; 1996 Apr; 12(7):1457-67. PubMed ID: 8622862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autocrine activation of an osteopontin-CD44-Rac pathway enhances invasion and transformation by H-RasV12.
    Teramoto H; Castellone MD; Malek RL; Letwin N; Frank B; Gutkind JS; Lee NH
    Oncogene; 2005 Jan; 24(3):489-501. PubMed ID: 15516973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.